[1]赵书元,余辉,傅琪琳△,等.芪胶升白胶囊联合重组人粒细胞刺激因子治疗肝癌患者 介入术后骨髓抑制疗效研究[J].陕西中医,2018,(10):1390-1392.
　Zhao Shuyuan,Yu Hui,Fu Qilin,et al.Observation on the curative effect of Qijiao Shengbai capsule combined with recombinant human granulocyte stimulating factor on treating bone marrow suppression after interventional therapy for patients with hepatocellular carcinoma[J].,2018,(10):1390-1392.
点击复制

芪胶升白胶囊联合重组人粒细胞刺激因子治疗肝癌患者 介入术后骨髓抑制疗效研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2018年10期
页码:
1390-1392
栏目:
临床研究
出版日期:
2018-12-31

文章信息/Info

Title:
Observation on the curative effect of Qijiao Shengbai capsule combined with recombinant human granulocyte stimulating factor on treating bone marrow suppression after interventional therapy for patients with hepatocellular carcinoma
文章编号:
DOI: 10.3969/j.issn.1000-7369.2018.10.023
作者:
赵书元1; 余辉1; 傅琪琳2△; 范文征1; 尚长青1
1.河南省驻马店市中心医院介入科 （驻马店463000），2.陕西省中医医院（西安710003）
Author(s):
Zhao Shuyuan; Yu Hui; Fu Qilin;  et al.
Departmentof Invasive Technology，Zhumadian Central Hospital in Henan Province(Zhumadian 463000)
关键词:
肝肿瘤 /中西医结合疗法@芪胶升白胶囊@重组人粒细胞刺激因子
Keywords:
Key words Liver neoplasms/ integrated Chinese traditional and western medicine therapy@Qijiao Shengbai capsule@Recombinant human granulocyte stimulating factor
分类号:
R735.7
文献标志码:
A
摘要:
摘要 目的：探讨芪胶升白胶囊联合重组人粒细胞刺激因子防治肝癌患者介入治疗术后骨髓抑制的临床效果。方法：选取原发性中晚期肝癌患者88例为研究对象。采用随机数字表法将患者分为治疗组和对照组，每组44例。所有患者接受经导管 TACE治疗，连续4个疗程化疗；术后所有患者均预防性皮下注射重组人粒细胞刺激因子，治疗组在此基础上加用芪胶升白胶囊。结果：治疗组化疗完成率为100%（44/44）显著高于对照组的88.64%（39/44）（P＜0.05）。治疗组化疗后WBC、Hb和PLT指标Ⅲ ～Ⅳ度骨髓抑制率明显轻于对照组（P＜0.05）。治疗组WBC恢复正常所需的时间显著低于对照组（P＜0.05）。治疗后两组CD4+和CD4+/CD8+均显著上升（P＜0.05），CD8+显著降低（P＜0.05），且观察组与对照组比较差异有统计学意义（P＜0.05）。结论：芪胶升白胶囊联合重组人粒细胞刺激因子对骨髓有较明显的保护作用，可显著减轻原发性肝癌TACE治疗对患者WBC、Hb和PLT的抑制程度，缩短骨髓抑制恢复时间，能改善机体的免疫功能，从而保证TACE的治疗延续。
Abstract:
Abstract Objective :To evaluate the prophylaxis and treatment effect of Qijiao Shengbai capsule combined with recombinant human granulocyte stimulating factor on bone marrow suppression after interventional therapy for patients with liver cancer. Methods:88 patients with primary advanced hepatocellular carcinoma were selected as the study subjects. Patients were divided into treatment group and control group by random number table method. All patients underwent transcatheter TACE treatment，the observation period of the two groups was 4 weeks. And patients were injected preventive subcutaneously with recombinant human granulocyte stimulating factor. The treatment group on this basis with the addition of Qijiao Shengbai capsule. Results：The rate of chemotherapy completion was 100.0% (44/44) in the treatment group and 88.64% in the control group (39/44),with significant difference (P＜0.05). The bone marrow suppression of WBC，Hb and PLT Ⅲ ~ Ⅳ was significantly lighter than those of the control group (P＜0.05). The time required for the WBC to return to normal treatment in the treatment group was significantly lower than that in the control group (P＜0.05). There was no significant difference in T cell subsets between the two groups before treatment (P＞0.05). The levels of CD4+ and CD4+ / CD8+ in the two groups were significantly increased (P＜0.05)，CD8+ was significantly decreased (P＜0.05)，and there was significant difference between the observation group and the control group (P＜0.05).Conclusion：The combination of Qijiao Shengbai capsule and recombinant human granulocyte stimulating factor has obvious protective effect on bone marrow，which can significantly reduce the degree of WBC，Hb and PLT in primary hepatocellular carcinoma (TACE)，and shorten the recovery time of myelosuppression. It can improve the immune function of the body and ensure the continuation of the treatment of TACE.

参考文献/References:


[1] 冯超，赵剑波，陈勇，等. 原发性肝癌切除术后预防性经肝动脉介入治疗: 肝动脉化疗栓塞术和化疗灌注术比较[J]. 介入放射学杂志，2014，23(8): 679-682.
[2]李娇，张晟，张瑾. 重组人粒细胞集落刺激因子预防乳腺癌化疗后骨髓抑制的疗效分析[J]. 中国癌症杂志，2014，24(12): 925-930.
[3]高远，王宇岭，冯军，等. 芪胶升白胶囊对晚期胃癌化疗患者骨髓抑制及免疫功能的影响[J]. 实用肿瘤杂志，2013，28(6): 657-659.
[4]中国抗癌协会肝癌专业委员会．原发性肝癌诊断标准[J].中华肝脏病杂志，2000，8(3):135.
[5]孙燕. 抗癌药急性及亚急性毒性反应分度标准 (WHO 标准)[J]. 癌症，1992，11(3): 24-25.
[6]李海. 解毒祛瘀论治原发性肝癌的临床研究[J]. 陕西中医，2016，37(1):60-61.
[7]谢菁，刘泉，吴灵芝. 芪胶升白胶囊对恶性消化道肿瘤化疗后骨髓抑制及免疫状态的影响[J]. 实用癌症杂志，2015,30(10):1462-1465.
[8]孙春霞，赵普辉，刘经选,等. 芪胶升白胶囊治疗恶性肿瘤化疗致骨髓抑制的临床观察[J]. 医学理论与实践，2012，25(17):2108-2109.
[9]吴航，令小峰. 不同白毛夏枯草提取物抗肝癌机制分析[J]. 陕西中医，2017，38(6):812-814.
[10]丁荣楣，王平，马丽君,等. 芪胶升白胶囊对肺癌放疗患者白细胞减少的疗效及生存质量的影响[J]. 现代肿瘤医学，2016，24(3):400-403.
[11]吴越，吴永强，洪日,等. 芪胶升白胶囊联合康复新液对乳腺癌根治术后创面溃疡的临床疗效[J]. 中成药，2016，38(5):989-992.
[12]张丽，包祖晓，冯长伟,等. 芪胶升白胶囊对非霍奇金淋巴瘤患者化疗后骨髓抑制的治疗作用观察[J]. 中华中医药学刊，2017，16(6):1533-1535.
[13]王莉彦，丰健宇，刘丹丹,等. 晚期肺癌化疗患者应用芪胶升白胶囊治疗对红细胞ATP酶活性的影响分析[J]. 中国卫生标准管理，2016，7(17):132-133.
[14]李冬梅，李炜青，刘顺清. 芪胶升白胶囊治疗白细胞减少症的疗效观察[J]. 临床医药文献电子杂志，2016，3(11):2195-2196.
[15]代春美，陈香，胡相卡,等. 芪胶升白胶囊联合环磷酰胺对S180荷瘤小鼠增效减毒作用研究[J]. 天然产物研究与开发，2016,16(7):1029-1034.
[16]王静雯，张新. 芪胶升白胶囊联合重组人粒细胞集落刺激因子治疗宫颈癌化疗后骨髓抑制随机平行对照研究[J]. 实用中医内科杂志，2017，31(6):28-30.
[17]王静文,张新.芪胶升白胶囊联合重组人粒细胞集落刺激因子治疗宫颈癌化疗后骨髓抑制随机平行对照研究[J].实用中医内科杂志，2016,30（1）：1-3.

更新日期/Last Update: 2019-01-07